Advanced Search

The story appears on

Page A11

July 19, 2018

GET this page in PDF

Free for subscribers

View shopping cart

Related News

Home 禄 Business 禄 Consumer

Ascentage raises US$150m to fund new cancer drugs

By Ding Yining | 00:01 UTC+8 July 19, 2018 | Print Edition

SUZHOU-BASED Ascentage Pharma said it has raised US$150 million in series C funding for its pipeline of innovative cancer drugs as Chinese drug developers move to turn lab work into new drug launches in the world’s largest pharmaceutical market.

The new financing will be used to fund its R&D and manufacturing facilities as well as new hiring at a time when the government is urging the introduction of innovative treatments for prevalent severe diseases, such as cancer and cardiovascular diseases, by encouraging startups in the pharmaceutical industry.

Ascentage plans to build its team up to 300 members within six months, and 400 by the end of next year.

“With this financing, we are well positioned to achieve key data milestones as we continue to advance our growing pipeline of novel small molecule candidates,” said Chairman and CEO Yang Dajun.

The latest round takes the total amount of capital raised by Ascentage to date to US$240 million, and was led by existing investors YuanMing Prudence Fund and Oriza Seed Venture Capital, as well as new investor Teng Yue Partners.

Consumer
锘

 

Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.

娌叕缃戝畨澶 31010602000204鍙

Email this to your friend


锘